Evaluating pain from stimuli and resulting emotional responses in non-clinical animals.
MD Biosciences is dedicated to the study of pain and neurodegenerative diseases. The understanding of pain and novel mechanisms requires a deep understanding of the science as well as the resources in terms of expertise and infrastructure to effectively study therapeutic candidates in early and translational phases.
As with any model, the right selection of species, stimuli, assessments, and end-point analysis leads to a quality study that brings insight into the condition and potential therapeutic. MD Biosciences expertise in study design contributes to predictive data from preclinical studies.
Measuring pain is often times straight forward using stimuli and measuring the resulting response. But the clinical situation not only evaluates response to the stimuli but the emotional component that patients report. In animal studies, we must rely on vocalization assessments and tests such as the open field to see how animals exhibit anxiety and behave emotionally as a result of the painful condition.
If you are ready to discuss how a partnership can support your development program, our scientists are eager to explore the possibilities with you. Like many other pharmaceutical and medical device developers, you can rely on predictive preclinical data when studies are designed right.